Capricor Therapeutics (NASDAQ:CAPR) Stock Price Crosses Above Fifty Day Moving Average of $4.20

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR – Get Rating) passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $4.20 and traded as high as $4.75. Capricor Therapeutics shares last traded at $4.65, with a volume of 33,139 shares changing hands.

Wall Street Analysts Forecast Growth

CAPR has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Capricor Therapeutics in a research report on Thursday, March 16th. StockNews.com started coverage on shares of Capricor Therapeutics in a research note on Thursday, May 18th. They set a “sell” rating on the stock.

Capricor Therapeutics Stock Down 0.9 %

The firm has a market cap of $117.51 million, a PE ratio of -3.97 and a beta of 3.99. The firm’s 50 day moving average is $4.20 and its 200-day moving average is $4.20.

Capricor Therapeutics (NASDAQ:CAPR – Get Rating) last announced its quarterly earnings data on Wednesday, March 15th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter. The company had revenue of $0.96 million for the quarter, compared to analyst estimates of $0.01 million. On average, analysts forecast that Capricor Therapeutics Inc will post -1.41 earnings per share for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

Large investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its stake in Capricor Therapeutics by 138.7% during the first quarter. Tower Research Capital LLC TRC now owns 8,770 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 5,096 shares during the period. Charles Schwab Investment Management Inc. purchased a new position in Capricor Therapeutics during the first quarter worth approximately $51,000. Renaissance Technologies LLC purchased a new position in Capricor Therapeutics during the third quarter worth approximately $61,000. Virtu Financial LLC purchased a new position in Capricor Therapeutics during the first quarter worth approximately $71,000. Finally, HighTower Advisors LLC raised its stake in Capricor Therapeutics by 17.8% during the fourth quarter. HighTower Advisors LLC now owns 19,885 shares of the biotechnology company’s stock worth $76,000 after purchasing an additional 3,001 shares during the period. Hedge funds and other institutional investors own 11.06% of the company’s stock.

About Capricor Therapeutics

(Get Rating)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.